Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma
Checkpoint inhibitor atezolizumab produces lasting responses in a rare aggressive lymphoma where treatment options are severely limited, potentially extending survival for heavily pretreated patients.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Sotatercept reduces bone morphogenetic protein signaling in patients…
A newly FDA-approved PAH drug may work through an unexpected mechanism, with blood-based biomarkers now enabling doctors to monitor whether the drug is actually engaging its target in individual patients.
Early cancer detection or preventionUrine tumor DNA testing identifies recurrence and monitors therapy…
Urine cancer DNA testing detects bladder cancer recurrence months earlier than standard surveillance, giving doctors a significant head start to intervene before tumors progress.
Early cancer detection or preventionUltra-sensitive detection of mutant KRAS in circulating tumor DNA…
Ultra-sensitive blood testing catches more actionable mutations in early pancreatic cancer, identifying high-risk patients who might benefit from stronger treatment before surgery.
Novel or significantly improved treatmentRAS pathway activation and microenvironmental adaptation as hallmarks…
A rare aggressive leukemia subtype that was historically excluded from treatment trials now has a molecular profile and non-invasive blood-based monitoring approach to enable better research and care.